Last A$0.61 AUD
Change Today 0.00 / 0.00%
Volume 449.9K
ACL On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 1:58 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd (ACL) Snapshot

Open
A$0.61
Previous Close
A$0.61
Day High
A$0.62
Day Low
A$0.61
52 Week High
09/11/14 - A$0.68
52 Week Low
04/11/14 - A$0.46
Market Cap
197.9M
Average Volume 10 Days
662.5K
EPS TTM
A$-0.02
Shares Outstanding
324.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALCHEMIA LTD (ACL)

Related News

No related news articles were found.

alchemia ltd (ACL) Related Businessweek News

No Related Businessweek News Found

alchemia ltd (ACL) Details

Alchemia Limited, a biotechnology company, develops human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies in Australia and the United States. Its technologies include HyACT, a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid as a drug delivery vehicle for a range of approved anti-cancer therapeutics; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. The company also provides generic fondaparinux, an anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, it develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer, as well as in the phase II investigator-sponsored trials that focuses on small cell lung cancer. The company has collaboration agreements with AstraZeneca AB to discover and develop novel small molecules against multiple targets; Merck Serono to develop HA-Irinotecan in combination with therapeutic antibody, Erbitux (cetuximab), for patients with metastatic colorectal cancer; and IMBcom Asset Management Company for conducting research based upon certain voltage gated ion channel biological targets and library compounds, as well as with University of Queensland for ion channel drug discovery. Alchemia Limited also has research agreement with Monash University; and Cancer Research Technology Limited. The company was founded in 1995 and is headquartered in Brisbane, Australia.

29 Employees
Last Reported Date: 08/29/14
Founded in 1995

alchemia ltd (ACL) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$185.6K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: A$235.7K
Vice President of Business Development
Total Annual Compensation: A$197.8K
Group Financial Controller
Total Annual Compensation: A$193.4K
Vice President of Drug Discovery
Total Annual Compensation: A$224.3K
Compensation as of Fiscal Year 2014.

alchemia ltd (ACL) Key Developments

Alchemia Limited Announces Consolidated Preliminary Earnings Results for the Full Year Ended June 30, 2014

Alchemia Limited announced consolidated preliminary earnings results for the full year ended June 30, 2014. For the year, the company reported total revenues of AUD 15,811,000 compared with AUD 24,297,000 for the same period a year ago. Loss from continuing operations before income tax was AUD 7,186,000 compared with AUD 5,043,000 for the same period a year ago. Net loss from continuing operations was AUD 6,924,000 or 2.1 cents per basic and diluted share compared with AUD 4,770,000 or 1.6 cents per basic and diluted share for the same period a year ago. Net cash flows used in operating activities was AUD 1,621,000 compared with AUD 13,524,000 for the same period a year ago. Purchase of property, plant and equipment was AUD 249,000 compared with AUD 94,000 for the same period a year ago.

Alchemia Limited Appoints Jenni Pilcher as Chief Financial Officer, Effective on September 1, 2014

Alchemia Limited announced the appointment of Ms. Jenni Pilcher as its Chief Financial Officer (CFO). Ms. Pilcher brings extensive financial leadership experience to Alchemia. She is currently the CFO of Mesoblast, where she has been part of the executive team for the past seven years, and she also serves as Company Secretary. Jenni's appointment is effective on September 1, 2014.

Alchemia Limited Announces First Patient Enrolled into Clinical Trial of HA-Irinotecan and Erbitux

Alchemia Limited announced that the first patient has been enrolled into the new clinical trial of HA-Irinotecan and Erbitux (cetuximab); the CHIME trial. This clinical trial is being conducted as an Investigator-Sponsored trial and is jointly supported by Alchemia and Merck Serono SA (Merck Serono). The trial is being led by principal investigator, Associate Professor Peter Gibbs. The primary objective of this study is to evaluate the safety of Alchemia's lead HyACT drug, HA-Irinotecan, as part of the FOLFIRI treatment regimen, in combination with Erbitux. The CHIME trial will enrol approximately 50 patients who are candidates for second-line treatment of metastatic colorectal cancer (mCRC) and it will take place at six to ten sites around Australia. The trial is scheduled to run for approximately 24 months.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACL:AU A$0.61 AUD 0.00

ACL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACL.
View Industry Companies
 

Industry Analysis

ACL

Industry Average

Valuation ACL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.1x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD, please visit www.alchemia.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.